A Randomized, Double-Blind, to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.

开始日期2023-09-27

申办/合作机构

Alexza Pharmaceuticals, Inc.

[+3]

CTR20232033 / Completed临床1期

一项在中国健康受试者中评价单次给予盐酸阿扑吗啡注射液（皮下注射）的药代动力学特征、安全性、耐受性的I 期、开放性临床研究

主要目的：评估在中国健康受试者中单次给予盐酸阿扑吗啡注射液（皮下注射）1 mg、2 mg、3 mg 的药代动力学特征；次要目的：评估在中国健康受试者中单次给予盐酸阿扑吗啡注射液（皮下注射）1 mg、2 mg、3 mg 的安全性和耐受性。

开始日期2023-07-13

申办/合作机构

翼思生物医药（苏州）有限公司

[+3]

NCT05529095 / Not yet recruiting临床4期IIT

Open Label and Placebo-Controlled Assessment of Sublingual Apomorphine (Kynmobi) as Adjunct Therapy for Patients With Refractory Restless Legs Syndrome

This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy. Investigators hypothesize that the study drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS patients, in addition to subjective responses.

开始日期2022-09-01

申办/合作机构

The Methodist Hospital Research Institute

[+1]

100 项与盐酸阿扑吗啡相关的临床结果

登录后查看更多信息

100 项与盐酸阿扑吗啡相关的转化医学

登录后查看更多信息

100 项与盐酸阿扑吗啡相关的专利（医药）

登录后查看更多信息

199

项与盐酸阿扑吗啡相关的文献（医药）

2024-05-01·Clinical and Translational Science

Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients

Article

作者: Tuk, Bert ; Merkus, Frans ; Thijssen, Eva ; Cakici, Michel ; van Velze, Veerle ; Kremer, Philip ; Klaassen, Erica ; van Laar, Teus ; Groeneveld, Geert Jan

AbstractApomorphine, used to treat OFF episodes in patients with Parkinson's disease (PD), is typically administered via subcutaneous injections. Administration of an oromucosal solution could offer a non‐invasive and user‐friendly alternative. This two‐part clinical study evaluated the safety, tolerability, pharmacokinetics (PK), and dose proportionality of a novel apomorphine hydrochloride oromucosal solution, as well as its relative bioavailability to subcutaneous apomorphine injection and apomorphine sublingual film. In part A of the study, 12 patients with PD received 2 mg oromucosal apomorphine (4% weight/volume) and 2 mg subcutaneous apomorphine in a randomized order, followed by 4 and 8 mg oromucosal apomorphine. In part B of the study, 13 patients with PD received 7 mg oromucosal apomorphine (7% weight/volume) and 30 mg sublingual apomorphine in a randomized order, followed by 14 mg oromucosal apomorphine. Washout between dose administrations in both study parts was at least 2 days. Safety, tolerability, and PK were assessed pre‐ and post‐dose. Both study parts showed that oromucosal apomorphine was generally well‐tolerated. Observed side effects were typical for apomorphine administration and included asymptomatic orthostatic hypotension, yawning, fatigue, and somnolence. Oromucosal apomorphine exposure increased with dose, although less than dose proportional. The mean (SD) maximum exposure reached with 14 mg oromucosal apomorphine was 753.0 (298.6) ng*min/mL (area under the plasma concentration–time curve from zero to infinity) and 8.0 (3.3) ng/mL (maximum plasma concentration). This was comparable to exposure reached after 2 mg subcutaneous apomorphine and approximately half of the exposure observed with 30 mg sublingual apomorphine. In summary, clinically relevant plasma concentrations could be reached in PD patients without tolerability issues.

2024-02-01·International Journal of Neuroscience

Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study

Article

作者: Ostrea, Marc C. ; Rosales, Raymond L. ; Joya-Tanglao, Michelle

BACKGROUNDApomorphine hydrochloride is used in the management of advanced Parkinson disease (PD), either as a rescue medication for off periods during levodopa therapy or as a maintenance pump medication. This is the first study to describe the effects of apomorphine in Filipino patients with PD.OBJECTIVETo evaluate the safety and efficacy of apomorphine ampules (APO-go®) pump infusion in the treatment of motor fluctuations in patients inadequately controlled on oral anti-Parkinson medications.METHODSPatients diagnosed with PD who developed motor fluctuations with levodopa were evaluated at baseline and at the end of the study using the Modified Hoehn and Yahr (H&Y) Scale, the Unified Parkinson's Disease Rating Scale (UPDRS) and the Abnormal Involuntary Movement Scale (AIMS). After initial assessment, patients were administered 20 ampules of apomorphine hydrochloride 10 mg/mL by infusion pump over 20 days. Intention-to-treat (ITT) analysis included all patients who completed at least one posttreatment assessment. Motor disability based on modified H&Y scores, motor function and complications of therapy pre- and posttreatment were compared using Wilcoxon Signed Rank test. Chi-squared test was used to compare outcomes by age and sex. Frequencies of adverse reactions were recorded to evaluate the tolerability of the medication.RESULTSTen patients (mean age 63 ± 9.7 years), 3 male and 7 female, were enrolled in the study. Patients were given apomorphine for at most 16 days. The doses used were 2.5 mg/0.50 mL (n = 2), 3 mg/0.60 mL (n = 6), 4 mg/0.80 mL (n = 1) and 7 mg/1.40 mL (n = 1). After obtaining the threshold dose, two patients discontinued treatment. Eight of nine patients showed significant improvement in H&Y scores after treatment (p < 0.017). There was marked improvement after 10 days of treatment in at least five of 10 patients in terms of motor function using UPDRS, which included tremor (p < 0.034), rigidity (p < 0.002), facial expression (p < 0.014), finger taps (p < 0.008), foot taps (p < 0.014) and gait (p < 0.006). Significant changes from pre- to posttreatment scores in the frequency of dyskinesias (p < 0.010) and dystonia (p < 0.025) were observed. Nine focus areas of AIMS showed significant improvements in the muscles of facial expression (p < 0.020), upper (p < 0.016) and lower extremities (p < 0.010), incapacitation by abnormal movement (p < 0.010) and patients' awareness of abnormal movements (p < 0.039). Six patients experienced adverse events, none of which were related to the study drug.CONCLUSIONApomorphine hydrochloride pump infusion therapy is potentially effective and safe in the treatment of motor fluctuations in Filipino patients with PD. This pilot study springboards safe engagements of Filipino PD patients in multicenter, large-scale trials.

2024-01-01·Pharmaceutical Research

Fabrication and Characterization of Dissolving Microneedles for Transdermal Drug Delivery of Apomorphine Hydrochloride in Parkinson’s Disease

Article

作者: Sakaue, Motoharu ; Yamamoto, Eiichi ; Ozawa, Aisa ; Ando, Daisuke ; Koide, Tatsuo ; Sato, Yoji ; Izutsu, Ken-Ichi ; Miyazaki, Tamaki

PURPOSEWe fabricated and characterized polyvinyl alcohol (PVA)-based dissolving microneedles (MNs) for transdermal drug delivery of apomorphine hydrochloride (APO), which is used in treating the wearing-off phenomenon observed in Parkinson's disease.METHODSWe fabricated MN arrays with 11 × 11 needles of four different lengths (300, 600, 900, and 1200 μm) by micromolding. The APO-loaded dissolving MNs were characterized in terms of their physicochemical and functional properties. We also compared the pharmacokinetic parameters after drug administration using MNs with those after subcutaneous injection by analyzing the blood concentration of APO in rats.RESULTSPVA-based dissolving MNs longer than 600 μm could effectively puncture the stratum corneum of the rat skin with penetrability of approximately one-third of the needle length. Although APO is known to have chemical stability issues in aqueous solutions, the drug content in APO-loaded MNs was retained at 25°C for 12 weeks. The concentration of APO after the administration of APO-loaded 600-μm MNs that dissolved completely in skin within 60 min was 81%. The absorption of 200-μg APO delivered by MNs showed a T_max of 20 min, C_max of 76 ng/mL, and AUC_{0-120 min} of 2,829 ng・min/mL, compared with a T_max of 5 min, C_max of 126 ng/mL, and AUC_{0-120 min} of 3,224 ng・min/mL for subcutaneous injection. The bioavailability in terms of AUC_{0-120 min} of APO delivered by MNs was 88%.CONCLUSIONAPO-loaded dissolving MNs can deliver APO via skin into the systemic circulation with rapid absorption and high bioavailability.

项与盐酸阿扑吗啡相关的新闻（医药）

2024-10-28

·GlobeNewswire-Health Care

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9 or IFI27 validating that knockdown of IRF9 and IFI27 as therapeutic targets for TGFB2 therapeutics. https://www.mdpi.com/3003472 The publications of this series are available at Pubmed as follow: 1) TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma. Qazi S, Trieu V. Int J Mol Sci. 2024 Oct 18;25(20):11221. doi: 10.3390/ijms252011221. PMID: 39457004 2) Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Trieu V, Maida AE, Qazi S. Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202. PMID: 38539537 Free PMC article. 3) Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients. Qazi S, Talebi Z, Trieu V. Biomedicines. 2024 Jan 15;12(1):191. doi: 10.3390/biomedicines12010191. PMID: 38255296 Free PMC article. 4) High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Uckun FM, Qazi S, Trieu V. Cancers (Basel). 2023 Mar 9;15(6):1676. doi: 10.3390/cancers15061676. PMID: 36980562 Free PMC article. Additional information on our current phase 3 can be found at: https://www.youtube.com/watch?v=5KqdbySDRKE About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

并购临床3期

2024-10-23

·GlobeNewswire-Health Care

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

AGOURA HILLS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Precision in Drug Discovery & Preclinical Summit. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://events.precision-globe.com/single-event/precision-drug-discovery-preclinical-summit-san-diego##. Dr. Chang and Dr. Zand are experienced nanomedicine and precision drug development dedicated to finding the cure for pancreatic and brain cancers. https://www.linkedin.com/in/wen-han-chang-106002139/ https://www.linkedin.com/in/tara-zand-phd-512042b5/ https://www.linkedin.com/posts/precision-evolution-global-inc_pddpsummit-sandiego-precisionevolutionglobal-activity-7253106596543619072-IqP5/ About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

并购

2024-08-20

·GlobeNewswire-Health Care

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Aug. 19, 2024 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD). The resubmission is now considered filed, with a user fee goal date (PDUFA date) of February 1, 2025. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. The content above comes from the network. if any infringement, please contact us to modify.

申请上市

100 项与盐酸阿扑吗啡相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02004	盐酸阿扑吗啡	G04BE07 N04BC07	DB00714

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
帕金森病	美国	MDD US Operations, LLC	2004-04-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
帕金森病	药物发现	美国	Sumitomo Pharma America, Inc.	2020-05-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02542696 (Phase 3 study, CTgov)	临床3期	精神运动障碍 \| 帕金森病	496	APL-130277	餘積網艱壓衊衊鹽醖繭(鹽繭顧築願觸選範膚襯) = 淵願製壓蓋製廠積鹹艱壓壓網鑰製艱簾蓋願繭 (願選壓餘顧願襯網鑰餘, 獵糧遞憲廠膚鹹齋願積 ~ 壓醖網鏇艱積淵觸糧築) 更多	-	2023-11-22
MDS2023	N/A	-	-	apomorphine sublingual film	(憲衊窪鑰夢餘選膚餘鹹) = 憲積積夢鬱構獵襯鹹淵繭簾窪廠衊糧蓋鹽蓋構 (選蓋醖憲願壓衊壓鹽衊 ) 更多	-	2023-08-27
MDS2023	N/A	-	-	apomorphine sublingual film	(憲衊窪鑰夢餘選膚餘鹹) = 選顧遞積齋蓋糧窪選壓繭簾窪廠衊糧蓋鹽蓋構 (選蓋醖憲願壓衊壓鹽衊 ) 更多	-	2023-08-27
MDS2022	N/A	药物不良反应	9,934	Apomorphine	鬱齋簾構壓製膚製製襯(醖繭範夢衊網衊壓糧壓) = 鬱願簾鹹衊觸齋遞簾製網窪選窪壓顧衊遞獵憲 (遞憲鑰鹽鑰鹽艱鬱鹽簾 ) 更多	-	2022-09-15
NCT02940912 (APOMORPHEE, Pubmed) 人工标引	临床4期	入睡和睡眠障碍 \| 帕金森病一线	46	apomorphine	範鑰觸襯觸醖襯鑰鹹鬱(鹽鹹鹽網鬱糧顧願夢餘) = 窪憲蓋鬱憲繭醖範鹽遞襯鹹廠膚壓膚願餘餘製 (構餘網築艱衊艱衊糧膚 ) 更多	积极	2022-05-01
NCT02940912 (APOMORPHEE, Pubmed) 人工标引	临床4期	入睡和睡眠障碍 \| 帕金森病一线	46	Placebo	範鑰觸襯觸醖襯鑰鹹鬱(鹽鹹鹽網鬱糧顧願夢餘) = 製觸構膚獵觸繭鑰壓構襯鹹廠膚壓膚願餘餘製 (構餘網築艱衊艱衊糧膚 ) 更多	积极	2022-05-01
NCT02469090 (not available, MDS2021)	临床3期	精神运动障碍 \| 帕金森病	141	Apomorphine Sublingual Film	範襯襯鹽衊獵願鏇餘窪(廠壓範網構餘簾廠糧襯) = Acute episodes of nausea varied by dose, occurring in 10/141 (7%) patients with 10 mg APL, 6/123 (5%) with 15 mg, 5/88 (6%) with 20 mg, 3/57 (5%) with 25 mg, 4/36 (11%) with 30 mg, and 2/20 (10%) with 35 mg. Most acute episodes of nausea were mild (57%), with 30% classified as moderate and 13% as severe. Vomiting occurred in 2 patients who experienced severe nausea and 1 patient who experienced moderate nausea. 餘鏇簾壓淵蓋繭製鏇觸 (遞鏇衊憲鏇繭廠壓糧製 )	积极	2021-09-17
NCT02542696 (Phase 3 study, MDS2021)	临床3期	帕金森病	-	Apomorphine Sublingual Film	(襯憲遞積積範鬱鹽選構) = 範觸鬱襯鑰衊夢夢衊鏇繭顧構顧鬱夢積獵艱鏇 (簾範鏇鏇簾選簾選遞鬱 ) 更多	积极	2021-09-17
NCT02542696 (Phase 3 study, MDS2021)	临床3期	帕金森病	-	Apomorphine Sublingual Film	(襯憲遞積積範鬱鹽選構) = 蓋製遞餘窪壓衊觸廠衊繭顧構顧鬱夢積獵艱鏇 (簾範鏇鏇簾選簾選遞鬱 ) 更多	积极	2021-09-17
NCT02542696 (Phase 3 study, MDS2021)	临床3期	帕金森病	397	Apomorphine Sublingual Film	(選鹹鏇襯鬱鏇選鑰膚糧) = 積鑰遞憲廠襯餘鏇襯憲鹹憲壓衊壓淵蓋夢襯簾 (鑰製願顧觸繭壓餘糧構 ) 更多	积极	2021-09-17
NCT02542696 (MDS2021)	临床3期	帕金森病	176	Apomorphine Sublingual Film	(製顧製構醖廠製夢範淵) = 繭築積構壓觸鏇衊觸衊積鹽範艱構鬱選簾鹹遞 (網夢壓積醖廠觸構襯憲 ) 更多	-	2021-09-17
NCT02006121 (TOLEDO, Pubmed)	临床3期	帕金森病维持	107	Apomorphine infusion	(選醖淵鹹鬱繭鏇窪選餘) = fatigue 襯夢齋夢壓鹽獵衊構襯 (廠願製鏇艱鹽製鹹齋繭 ) 更多	-	2021-01-12
PC and LTS study (MDS2020)	N/A	帕金森病	425	Apomorphine sublingual film	積齋簾膚窪顧襯繭積繭(糧鹹壓鬱糧獵鹹鹽糧鏇) = TEAEs of dyskinesia were not reported in the PC study and occurred in 7% (28/425) of patients in the LTS study, with no apparent dose relationship. 鬱蓋範廠築鹹簾窪鏇觸 (構鹹蓋廠選餘糧鹽鬱鏇 )	积极	2020-09-12
PC and LTS study (MDS2020)	N/A	帕金森病	425	Placebo		积极	2020-09-12